DrugPatentWatch Database Preview
Upadacitinib - Generic Drug Details
» See Plans and Pricing
What are the generic drug sources for upadacitinib and what is the scope of freedom to operate?
Upadacitinib
is the generic ingredient in one branded drug marketed by Abbvie Inc and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.Upadacitinib has one hundred and forty-three patent family members in thirty-nine countries.
One supplier is listed for this compound.
Summary for upadacitinib
| International Patents: | 143 |
| US Patents: | 6 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 28 |
| Clinical Trials: | 25 |
| Patent Applications: | 166 |
| DailyMed Link: | upadacitinib at DailyMed |
Recent Clinical Trials for upadacitinib
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| AbbVie | Phase 1 |
| AbbVie | Phase 2 |
| AbbVie | Phase 3 |
US Patents and Regulatory Information for upadacitinib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie Inc | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-001 | Aug 16, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Abbvie Inc | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-001 | Aug 16, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Abbvie Inc | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-001 | Aug 16, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Abbvie Inc | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-001 | Aug 16, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Abbvie Inc | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-001 | Aug 16, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Abbvie Inc | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-001 | Aug 16, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Abbvie Inc | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-001 | Aug 16, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for upadacitinib
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 2299821 | Start Trial |
| Brazil | PI0915374 | Start Trial |
| Costa Rica | 20160007 | Start Trial |
| Australia | 2020201390 | Start Trial |
| China | 108368121 | Start Trial |
| Israel | 261778 | Start Trial |
| Colombia | 6561771 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for upadacitinib
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2506716 | PA2020505 | Lithuania | Start Trial | PRODUCT NAME: UPADACITINIBAS; REGISTRATION NO/DATE: EU/1/19/1404 20191216 |
| 2506716 | CA 2020 00011 | Denmark | Start Trial | PRODUCT NAME: UPADACITINIB; REG. NO/DATE: EU/1/19/1404 20191218 |
| 2506716 | 2090010-6 | Sweden | Start Trial | PRODUCT NAME: UPADACITINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/19/1404 20191218 |
| 2506716 | 122020000011 | Germany | Start Trial | PRODUCT NAME: UPADACITINIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1404 20191216 |
| 2506716 | LUC00149 | Luxembourg | Start Trial | PRODUCT NAME: UPADACITINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/19/1404 20191218 |
| 2506716 | 2020C/505 | Belgium | Start Trial | PRODUCT NAME: UPADACITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/19/1404 20191218 |
| 2506716 | 301035 | Netherlands | Start Trial | PRODUCT NAME: UPADACITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/19/1404 20191218 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
